Marty-Ané Charles-Henri, Canaud Ludovic, Solovei Laurence, Alric Pierre, Berthet Jean-Philippe
Department of Thoracic, Cardiac and Vascular Surgery, Arnaud de Villeneuve Hospital, Montpellier, France.
Interact Cardiovasc Thorac Surg. 2013 Jul;17(1):36-43. doi: 10.1093/icvts/ivt146. Epub 2013 Apr 16.
Evaluation of the feasibility, safety and oncological validity of video-assisted thoracic lobectomy (VATS). The VATS study exclusion criteria included T3 or T4 tumours, central hilar tumours, tumours visible on bronchoscopy requiring sleeve resection, hilar lymphadenopathy, N2 disease, history of neoadjuvant chemotherapy or radiation, previous thoracic surgery or pleurodesis.
A retrospective study of 410 patients (143 women, mean age 61.5 ± 13.1 years (84-15) treated by VATS lobectomy between 1996 and 2011 was performed at our institution. VATS lobectomy was performed for lung cancer (n = 364, 88.9%), pulmonary metastasis (n = 25, 5.8%) and non-neoplastic diseases (n = 21, 5.1%). In lung cancer, a systematic radical lymph node dissection was performed.
There was no intraoperative death. The conversion rate was 6.1% (n = 25): bleeding (n = 4), extended pleural adhesion (n = 6, 1.4%), technical difficulty (n = 6, 1.4%), tumour extension to the fissure or mediastinum or adenopathy (n = 7, 1.7%) and intolerance to one-lung ventilation (n = 2, 0.4%). The postoperative mortality rate was 1.2% (n = 5). Major complications occurred in 21 patients (5.1%). The mean number of mediastinal nodes removed was 14.6 (5-44) and 42 patients (10.2%) presented N2 disease at the definitive staging. The mean operating time was 152 (85-315) min. The mean drainage duration was 3.2 days (1-15). Mean postoperative length of hospital stay before return at home was 6.8 days (3-75) and 5.5 days in patients without major complications. There was no port site recurrence. Kaplan-Meier 3-year survival rates were 76.5% for Stage I and 87.3% for Stage IA, 58% for Stage II and 61% for Stage III.
VATS lobectomy is an acceptable alternative and seems equivalent to open lobectomy in terms of complications and oncological value. Our experience prompts us to consider VATS lobectomy for early stage NSCLC as the first surgical approach in view of the improvement in outcome, provided that the procedure is performed by a surgeon with adequate experience with this approach.
评估电视辅助胸腔镜肺叶切除术(VATS)的可行性、安全性及肿瘤学有效性。VATS研究的排除标准包括T3或T4期肿瘤、中央型肺门肿瘤、支气管镜下可见需行袖状切除术的肿瘤、肺门淋巴结肿大、N2期疾病、新辅助化疗或放疗史、既往胸部手术史或胸膜固定术史。
对1996年至2011年间在本机构接受VATS肺叶切除术的410例患者(143例女性,平均年龄61.5±13.1岁(84 - 15岁))进行回顾性研究。VATS肺叶切除术用于治疗肺癌(n = 364,88.9%)、肺转移瘤(n = 25,5.8%)和非肿瘤性疾病(n = 21,5.1%)。对于肺癌患者,进行了系统性根治性淋巴结清扫。
术中无死亡病例。中转开胸率为6.1%(n = 25):出血(n = 4)、广泛胸膜粘连(n = 6,1.4%)、技术困难(n = 6,1.4%)、肿瘤侵犯至肺裂或纵隔或存在淋巴结病(n = 7,1.7%)以及单肺通气不耐受(n = 2,0.4%)。术后死亡率为1.2%(n = 5)。21例患者(5.1%)发生主要并发症。清扫的纵隔淋巴结平均数量为14.6个(5 - 44个),42例患者(10.2%)在最终分期时存在N2期疾病。平均手术时间为152分钟(85 - 315分钟)。平均引流时间为3.2天(1 - 15天)。术后平均住院时间(至出院)为6.8天(3 - 75天),无主要并发症的患者为5.5天。无切口部位复发。I期患者的Kaplan - Meier 3年生存率为76.5%,IA期为87.3%,II期为58%,III期为61%。
VATS肺叶切除术是一种可接受的替代方法,在并发症和肿瘤学价值方面似乎与开放性肺叶切除术相当。我们的经验促使我们考虑将VATS肺叶切除术作为早期非小细胞肺癌的首选手术方法,鉴于其疗效的改善,前提是该手术由对此方法有足够经验的外科医生进行。